Book Chapters
1. Rospond RM, Faulkner M. Head and Neck. In: Rhonda Jones, Raylene Rospond, editors. Patient Assessment in Pharmacy Practice. Baltimore, MD: Lippincott Williams & Wilkins; 2003. p. 157-74 (1st Edition).
2. Faulkner M, Rospond RM. Head and Neck. In: Rhonda Jones, Raylene Rospond, editors. Patient Assessment in Pharmacy Practice. Baltimore, MD: Lippincott Williams & Wilkins; 2008. p. 166-190 (2nd Edition).
Articles (Refereed)
1. Faulkner MA. Smoking cessation: an economic analysis and review of varenicline. Clinicoeconomics and Outcomes Research 2009;1:25-34. Available at http://www.dovepress.com/articles.php?article_id=3288.
2. Faulkner MA. Initiating and monitoring pharmacotherapy in patients with Parkinson's disease. US Pharmacist/PowerPak CE. February, 2009. Program numbers 430-000-09-003-H01-P; 430-000-09-003-H01-T. Available at http://tinyurl.com/d2yq8o.
3. Faulkner MA. Early versus delayed diagnosis and treatment of Parkinson's disease: what you need to know. US Pharmacist/PowerPak CE. December, 2008. Program numbers 430-000-08-025-H01-P; 430-000-08-025-H01-T. Available at http://tinyurl.com/95tqv4.
4. Coover K, Ryan-Haddad A, Faulkner M, Hilleman D. Prevalence, treatment and control of hypertension in residents of skilled nursing facilities. Consult Pharm 2008;23(4):317-232.
5. Ryan-Haddad A, Coover K, Faulkner M. A pharmacist's introduction to the effects of aging on patients with cerebral palsy. Consult Pharm 2007;22(8):669-74.
6. Stading JA, Faulkner MA, Skrabal MZ, Chock A. Effect of tobacco on INR (letter). J Health-Syst Pharm 2007;64:805.
7. Stading JA, Chock A, Faulkner MA, Skrabal MA. Effects of prednisone on the International Normalized Ratio. Am J Health-Syst Pharm 2006;63:2354-56.
8. Faulkner MA. The role of the pharmacist in the manangement of parkinson's disease: its symptoms and comorbidities. US Pharmacist/PowerPak CE. September, 2006. Program number 430-000-06-032-H01. Available at http://tinyurl.com/9m5sv9
9. Faulkner MA, Lenz TL, Stading JA. Cost-effectiveness of smoking cessation and the implications for COPD. International Journal of COPD 2006;1(3):279-87.
10. Lenz TL, Faulkner MA, Monaghan MS. Assessing the use of two-way interactive video (TWIV) conferencing to offer heart failure continuing education to rural pharmacists. J Pharm Teaching 2006;13(1):29-36.
11. Stading JA, Chock AWY, Skrabal MZ, Faulkner MA. Development of diabetes after gatifloxacin therapy. Am J Health-Syst Pharm 2005;62:293-5.
12. Faulkner MA, Ryan-Haddad AM, Lenz TL, Degner K. Osteoporosis in long-term care residents with multiple sclerosis. Consult Pharm 2005;20:128-36.
13. Hilleman DE, Faulkner MA, Monaghan MS. Cost of a pharmacist-directed intervention to increase treatment of hypercholesterolemia. Pharmacotherapy 2004;24:1077-83.
14. Lenz TL, Faulkner MA, Ryan-Haddad A. Rosuvastatin: A new HMG-CoA reductase inhibitor for the treatment of dyslipidemia. Advances in Pharmacy 2004;2:136-145.
15. Lenz TL, Lenz NJ, Faulkner MA. Potential interactions between exercise and drug therapy. Sports Medicine 2004;34:293-306.
16. Faulkner MA, Mears AJ, Adams P, Biring T, Frock J, Dunlay R. Can selective beta-blockers be prescribed safely for hemodialysis patients? A retrospective review. Hospital Pharmacy 2004;39:144-48.
17. Faulkner MA, Hilleman DE. Pharmacologic treatment of COPD: Past, present, and future. Pharmacotherapy 2003;23(10):1300-1315.
18. Faulkner MA, Bertoni JM, Lenz TL. Gabapentin for the treatment of tremor. Ann Pharmacother 2003;37:282-6.
19. Faulkner MA, Hilleman DE. The economic impact of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2002;3(3):219-228.
20. Stading JA, Skrabal MZ, Faulkner MA. Seven cases of interaction between warfarin and cyclooxygenase-2 inhibitors. Am J Health-Syst Pharm 2001;58:2076-80.
21. Faulkner MA, Hilleman DE, Destache CJ, Mooss AN. Potential influence of timing of low-density lipoprotein cholesterol evaluation in patients with acute coronary syndrome. Pharmacotherapy 2001;21(9):1055-60.
22. Hilleman DE, Reyes AP, Wurdeman RL, Faulkner M. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension. J Hum Hypertens 2001;15:559-65.
23. Faulkner MA, Hilleman DE. Amlodipine/benazepril: fixed dose combination therapy for hypertension. Expert Opin Pharmacother 2001;2(1):165-78.
24. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counseling on compliance and effectiveness of combination lipid lowering therapy in patients undergoing coronary artery revascularization: A randomized controlled trial. Pharmacotherapy 2000;20(4):410-416.
25. Nair CK, Faulkner MA. Newer antihypertensive drug therapies: Are they better for pulmonary patients? J Crit Illness 2000;15(8):437-446.